Total submissions: 10
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV000120970 | SCV000168413 | benign | not specified | 2014-01-08 | criteria provided, single submitter | clinical testing | This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease. |
Genetic Services Laboratory, |
RCV000120970 | SCV000247342 | benign | not specified | 2018-08-14 | criteria provided, single submitter | clinical testing | |
Invitae | RCV001082312 | SCV000252621 | benign | Fanconi anemia | 2019-12-31 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV000574575 | SCV000673295 | likely benign | Hereditary cancer-predisposing syndrome | 2018-12-05 | criteria provided, single submitter | clinical testing | In silico models in agreement (benign);Other data supporting benign classification;Other strong data supporting benign classification |
Integrated Genetics/Laboratory Corporation of America | RCV000590373 | SCV000695425 | benign | not provided | 2016-04-29 | criteria provided, single submitter | clinical testing | Variant summary: The c.1394A>G variant affects a non-conserved nucleotide, resulting in amino acid change from Gln to Arg. 5/5 in-silico tools predict benign outcome for this variant. This variant is found in 120/120326 control chromosomes at a frequency of 0.0009973, predominantly observed in African subpopulation in ExAC with observed MAF of 1%. This frequency exceeds the maximal expected frequency of a pathogenic allele (0.0017678), suggesting this variant is likely a benign polymorphism especially for Africans. This variant has been reported in the literature (Gibson_1996) in both cohorts of affected and control individuals and was classified by authors as a polymorphism. One patients unaffected parent who was obligated heterozygous carrier was genotyped to be homozygote for this variant, further supporting the neutral effect of this variant. In addition, multiple clinical laboratory/reputable database classified this variant as benign/likely benign, without evidence to independently evaluate. Taken together, the variant was classified as Benign. |
Mendelics | RCV000988196 | SCV001137833 | likely benign | Fanconi anemia, complementation group A | 2019-05-28 | criteria provided, single submitter | clinical testing | |
Illumina Clinical Services Laboratory, |
RCV001169818 | SCV001332595 | likely benign | Fanconi anemia, complementation group C | 2018-01-13 | criteria provided, single submitter | clinical testing | This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score and internal cut-off values, a variant classified as likely benign is not then subjected to further curation. The score for this variant resulted in a classification of likely benign for this disease. |
ITMI | RCV000120970 | SCV000085138 | not provided | not specified | 2013-09-19 | no assertion provided | reference population | |
Leiden Open Variation Database | RCV000590373 | SCV001365338 | uncertain significance | not provided | 2020-02-28 | no assertion criteria provided | curation | Curator: Arleen D. Auerbach. Submitter to LOVD: Arleen D. Auerbach. |
Natera, |
RCV001274610 | SCV001458894 | likely benign | Fanconi anemia, group C | 2020-04-12 | no assertion criteria provided | clinical testing |